1. Home
  2. MNTK vs CBIO Comparison

MNTK vs CBIO Comparison

Compare MNTK & CBIO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • MNTK
  • CBIO
  • Stock Information
  • Founded
  • MNTK 1980
  • CBIO 2003
  • Country
  • MNTK United States
  • CBIO United States
  • Employees
  • MNTK N/A
  • CBIO N/A
  • Industry
  • MNTK Natural Gas Distribution
  • CBIO
  • Sector
  • MNTK Utilities
  • CBIO
  • Exchange
  • MNTK Nasdaq
  • CBIO Nasdaq
  • Market Cap
  • MNTK 306.2M
  • CBIO 308.0M
  • IPO Year
  • MNTK 2021
  • CBIO N/A
  • Fundamental
  • Price
  • MNTK $2.15
  • CBIO $14.29
  • Analyst Decision
  • MNTK Hold
  • CBIO Strong Buy
  • Analyst Count
  • MNTK 3
  • CBIO 5
  • Target Price
  • MNTK $3.33
  • CBIO $25.60
  • AVG Volume (30 Days)
  • MNTK 223.8K
  • CBIO 98.3K
  • Earning Date
  • MNTK 08-06-2025
  • CBIO 07-31-2025
  • Dividend Yield
  • MNTK N/A
  • CBIO N/A
  • EPS Growth
  • MNTK N/A
  • CBIO N/A
  • EPS
  • MNTK 0.02
  • CBIO N/A
  • Revenue
  • MNTK $181,341,000.00
  • CBIO N/A
  • Revenue This Year
  • MNTK $3.74
  • CBIO N/A
  • Revenue Next Year
  • MNTK $3.88
  • CBIO N/A
  • P/E Ratio
  • MNTK $116.00
  • CBIO N/A
  • Revenue Growth
  • MNTK N/A
  • CBIO N/A
  • 52 Week Low
  • MNTK $1.68
  • CBIO $10.83
  • 52 Week High
  • MNTK $6.04
  • CBIO $21.40
  • Technical
  • Relative Strength Index (RSI)
  • MNTK 51.51
  • CBIO 52.92
  • Support Level
  • MNTK $1.98
  • CBIO $13.50
  • Resistance Level
  • MNTK $2.26
  • CBIO $16.00
  • Average True Range (ATR)
  • MNTK 0.10
  • CBIO 0.79
  • MACD
  • MNTK 0.03
  • CBIO 0.16
  • Stochastic Oscillator
  • MNTK 72.50
  • CBIO 39.68

About MNTK Montauk Renewables Inc.

Montauk Renewables Inc is a renewable energy company. It specializes in the recovery and processing of biogas from landfills and other non-fossil fuel sources for beneficial use as a replacement for fossil fuels. The firm develops, owns, and operates RNG projects that supply renewable fuel into the transportation and electrical power sectors. Montauk operates in two segments namely Renewable Natural Gas and Renewable Electricity Generation. It generates a majority of its revenue from the Renewable Natural Gas segment.

About CBIO Crescent Biopharma Inc. Common Stock

Crescent Biopharma Inc is a biopharmaceutical company developing novel therapeutics to treat solid tumors, led by CR-001, a proprietary anti-PD-1/anti-VEGF bispecific antibody. Crescent believes CR-001 has the potential to deliver improved clinical efficacy and safety over pembrolizumab. CR-001 is a new molecular entity designed to replicate the functional properties of ivonescimab, a cooperative bispecific anti-PD-1/anti-VEGF antibody in development by Akeso Biopharma and Summit Therapeutics that delivered improved efficacy in a head-to-head Phase 3 clinical trial versus Keytruda in non-small cell lung cancer. Crescent is advancing its second and third programs, CR-002 and CR-003, which are antibody drug conjugates (ADCs) against validated oncology targets.

Share on Social Networks: